CHICAGO--(EON: Enhanced Online News)--Paul Burton, the CEO of ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings is scheduled to present at Biotech Showcase as part of the J.P. Morgan 35th Annual Healthcare Conference Week in San Francisco. The presentation will take place on Wednesday January 11, 2017 at 3:30 pm PT at the Hilton San Francisco Union Square, 333 O’Farrell Street at the Ballroom Level. Mr. Burton will be discussing ResQ Pharma’s plans to attain regulatory market approval for LRT by 2018.
According to the Center for Disease Control and Prevention (CDC) 47,055 people died in 2014 from drug overdoses in the US. ResQ Pharma is energized about the opportunity to better address the situation by commercializing a life-saving therapy.
About LipidRescueTM Therapy (LRT)
ResQ Pharma's lead product candidate is LRT, which refers to the administration of a lipid emulsion with the intent of reducing the life-threatening clinical manifestations of toxicity from excessive doses of certain lipophilic drugs. It is already the opinion of the American Heart Association and American College of Medical Toxicology that where there is serious hemodynamic instability from local anesthetic drugs with high lipid solubility, LRT is a reasonable consideration for therapy, even if patient is not in cardiac arrest.
About ResQ Pharma
ResQ Pharma, Inc., is a biopharmaceutical company created to ensure reliable, global use of LRT, a treatment for various lipophilic drug overdoses and poisonings. For more information on ResQ Pharma, please visit www.LipidRescue.com. We are members of iBIO’s PROPEL, EnterpriseWorks Chicago, Chicago Founders Circle, The BUNKER and MATTER! We are also a Qualified New Business Venture for the Illinois Investment Tax Credit Program. DLA Piper, LLP provided legal counsel for the financing.
About Paul Burton, J.D., M.B.A.
Mr. Paul Burton has served as the CEO of ResQ Pharma since July 2015. He is a former investment banker having started his career in corporate finance with Salomon Brothers / Salomon Smith Barney in New York City in 1998 upon completion of both law school and business school at the University of Illinois at Urbana-Champaign. More recently he has worked with several entrepreneurial ventures in healthcare. Mr. Burton is also a former U.S. Regular Army Commissioned Officer (Infantry).
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "believes," "potential," "proposed," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, analyses or current expectations concerning, among other things: our expectations regarding the clinical effectiveness and safety of our product candidates and results of studies; and the timing of and our ability to obtain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates and advancing studies for LRT. Any forward-looking statements in this press release speak only as of the date of this press release.